It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in ...

Novavax (NASDAQ:NVAX) said that it has officially transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi (NASDAQ:SNY) within the European Union. As a result of this ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

Novavax is pushing ahead with plans to slim down with a deal to offload one its locations in Maryland and surrounding property, which is expected to net $60 million in cash for the vaccine maker.

In the latest close session, Novavax (NVAX) was down 4.02% at $9.08. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 0.71%.